430 related articles for article (PubMed ID: 30974033)
101. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
Zhang Z; Zhang Q; Tan Y; Chen Y; Zhou X; Liu S; Yu J
Front Endocrinol (Lausanne); 2023; 14():1149328. PubMed ID: 37484944
[TBL] [Abstract][Full Text] [Related]
102. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.
Wei XB; Wei W; Ding LL; Liu SY
Prim Care Diabetes; 2021 Apr; 15(2):208-211. PubMed ID: 32912710
[TBL] [Abstract][Full Text] [Related]
103. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
Silverii GA; Monami M; Gallo M; Ragni A; Prattichizzo F; Renzelli V; Ceriello A; Mannucci E
Diabetes Obes Metab; 2024 Mar; 26(3):891-900. PubMed ID: 38018310
[TBL] [Abstract][Full Text] [Related]
104. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
[TBL] [Abstract][Full Text] [Related]
105. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis.
Pinto LC; Falcetta MR; Rados DV; Leitão CB; Gross JL
Sci Rep; 2019 Feb; 9(1):2375. PubMed ID: 30787365
[TBL] [Abstract][Full Text] [Related]
106. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.
Yuan X; Gao Z; Hao Z; Ma H; Duan K; Yang C
Medicine (Baltimore); 2023 Oct; 102(43):e35739. PubMed ID: 37904378
[TBL] [Abstract][Full Text] [Related]
107. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.
Kapoor I; Sarvepalli SM; D'Alessio D; Grewal DS; Hadziahmetovic M
Surv Ophthalmol; 2023; 68(6):1071-1083. PubMed ID: 37454782
[TBL] [Abstract][Full Text] [Related]
108. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.
Malhotra K; Katsanos AH; Lambadiari V; Goyal N; Palaiodimou L; Kosmidou M; Krogias C; Alexandrov AV; Tsivgoulis G
J Neurol; 2020 Jul; 267(7):2117-2122. PubMed ID: 32246253
[TBL] [Abstract][Full Text] [Related]
109. Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.
Simental-Mendía LE; Sánchez-García A; Linden-Torres E; Simental-Mendía M
Br J Clin Pharmacol; 2021 Nov; 87(11):4140-4149. PubMed ID: 33835520
[TBL] [Abstract][Full Text] [Related]
110. Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.
Svensson AM; Toll A; Lebrec J; Miftaraj M; Franzén S; Eliasson B
Diabetes Obes Metab; 2021 Mar; 23(3):720-729. PubMed ID: 33289287
[TBL] [Abstract][Full Text] [Related]
111. Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.
Wang Y; Yao M; Wang J; Liu H; Zhang X; Zhao L; Hu X; Guan H; Lyu Z
Front Endocrinol (Lausanne); 2022; 13():818537. PubMed ID: 35370959
[TBL] [Abstract][Full Text] [Related]
112. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
Karakasis P; Patoulias D; Pamporis K; Stachteas P; Bougioukas KI; Klisic A; Fragakis N; Rizzo M
Metabolism; 2023 Dec; 149():155710. PubMed ID: 37852529
[TBL] [Abstract][Full Text] [Related]
113. Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Ida S; Kaneko R; Imataka K; Okubo K; Shirakura Y; Azuma K; Fujiwara R; Takahashi H; Murata K
Heart Fail Rev; 2021 Sep; 26(5):1151-1158. PubMed ID: 32080782
[TBL] [Abstract][Full Text] [Related]
114. The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis.
Merza N; Akram M; Mengal A; Rashid AM; Mahboob A; Faryad M; Fatima Z; Ahmed M; Ansari SA
Curr Probl Cardiol; 2023 May; 48(5):101602. PubMed ID: 36682393
[TBL] [Abstract][Full Text] [Related]
115. Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.
Barkas F; Elisaf M; Milionis H
Eur J Neurol; 2019 Apr; 26(4):559-565. PubMed ID: 30629331
[TBL] [Abstract][Full Text] [Related]
116. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
Minerva Endocrinol (Torino); 2023 Jun; 48(2):206-213. PubMed ID: 32720500
[TBL] [Abstract][Full Text] [Related]
117. Effects of GLP-1 receptor agonists on neurological complications of diabetes.
García-Casares N; González-González G; de la Cruz-Cosme C; Garzón-Maldonado FJ; de Rojas-Leal C; Ariza MJ; Narváez M; Barbancho MÁ; García-Arnés JA; Tinahones FJ
Rev Endocr Metab Disord; 2023 Aug; 24(4):655-672. PubMed ID: 37231200
[TBL] [Abstract][Full Text] [Related]
118. Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.
Li X; Song Y; Guo T; Xiao G; Li Q
Diabetes Metab; 2022 Sep; 48(5):101366. PubMed ID: 35760374
[TBL] [Abstract][Full Text] [Related]
119. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.
Iqbal J; Wu HX; Hu N; Zhou YH; Li L; Xiao F; Wang T; Jiang HL; Xu SN; Huang BL; Zhou HD
Obes Rev; 2022 Jun; 23(6):e13435. PubMed ID: 35194917
[TBL] [Abstract][Full Text] [Related]
120. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Luo G; Liu H; Lu H
Br J Clin Pharmacol; 2016 Jan; 81(1):78-88. PubMed ID: 27099876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
